iBio, Inc. (IBIO)

1.7900 -0.0800 (-4.28%) At close: 04:00PM EDT

iBio, Inc.

11750 Sorrento Valley Road
Suite 200
San Diego, CA 92121
United States
979-446-0027
https://www.ibioinc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 26

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Martin B. Brenner D.V.M., Ph.D.	CEO, Chief Scientific Officer & Director	577.31k	N/A	1970
Mr. Felipe Duran	Chief Financial Officer	1.07M	N/A	1979
Mr. Marc Banjak J.D.	Chief Legal Officer	N/A	N/A	N/A
Ms. Kristi Sarno	Senior VP of Business Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company's vaccines and therapeutics in preclinical development. Its EngageTx™ technology targets bi-specific molecules and its pre-clinical data demonstrates the ability to generate multiple hits creating sequence diversity and promoting Human-Cyno cross reactivity while mitigating cytokine release. The company also has ShieldTx™, a patent-pending antibody masking technology designed to enable specific targeted antibody delivery to diseased tissue without harming healthy tissue. The company was incorporated in 2008 and is headquartered in San Diego, California.

Corporate governance

iBio, Inc.’s ISS governance QualityScore as of 18 September 2024 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.